scholarly journals Seven-day Green Tea Supplementation Revamps Gut Microbiome and Caecum/Skin Metabolome in Mice from Stress

2019 ◽  
Vol 9 (1) ◽  
Author(s):  
Eun Sung Jung ◽  
Jong il Park ◽  
Hyunjoon Park ◽  
Wilhelm Holzapfel ◽  
Jae Sung Hwang ◽  
...  
Keyword(s):  
Stress Response ◽  
Green Tea ◽  
Epigallocatechin Gallate ◽  
Skin Barrier ◽  
Intestinal Microbiome ◽  
Skin Barrier Function ◽  
Short Term ◽  
Positive Effects ◽  
Uv Stress ◽  
Tea Extract

AbstractGreen tea supplementation has beneficial health effects. However, its underlying mechanisms, such as effects on modulating the intestinal microbiome and endogenous metabolome, particularly following short-term supplementation, are largely unclear. We conducted an integrative metabolomics study to evaluate the effects of short-term (7-day) supplementation of green tea extract (GTE) or its components, epigallocatechin gallate, caffeine, and theanine, on the caecum microbiota and caecum/skin metabolome in mice. Further, we established an integrative metabolome-microbiome model for correlating gut and skin findings. The effects of short-term supplementation with dietary compounds were evaluated with respect to UV stress response, with GTE showing the most remarkable effects. Biplot analysis revealed that Bifidobacteria and Lactobacillus spp. were considerably influenced by short-term GTE supplementation, while Clostridium butyricum was significantly increased by UV stress without supplementation. GTE supplementation helped the skin metabolome defend against UV stress. Interestingly, a significant positive correlation was observed between caecum bacteria (Bifidobacteria, Lactobacillus spp.) and metabolites including skin barrier function-related skin metabolites, caecal fatty acids, and caecal amino acids. Overall, 7-day GTE supplementation was sufficient to alter the gut microbiota and endogenous caecum/skin metabolome, with positive effects on UV stress response, providing insight into the mechanism of the prebiotic effects of GTE supplementation.

Isolation of Epigallocatechin Gallate from Green Tea and its Effects on Probiotics and Pathogenic Bacteria

2017 ◽  
Vol 17 (1) ◽  
pp. 69-77
Author(s):  
Tu Lijun ◽  
Sun Hanju ◽  
He Shudong ◽  
Zhu Yongsheng ◽  
Yu Ming ◽  
...  
Keyword(s):  
Mass Spectrometry ◽  
Escherichia Coli ◽  
Green Tea ◽  
Lactobacillus Acidophilus ◽  
Pathogenic Bacteria ◽  
Epigallocatechin Gallate ◽  
Microbial Populations ◽  
Medium Ph ◽  
Bioactive Substance ◽  
Tea Extract

The aim of this study was to investigate epigallocatechin gallate (EGCG) prebiotics activities systematically which was reported as a bioactive substance. Therefore, EGCG was separated by water extraction, resin purification and prep-HPLC. Then the production of EGCG was confirmed by HPLC and mass spectrometry (MS) analysis and its purify was 97.23%. EGCG extractive and green tea extract (GTE) were further incubated with Bifidobacterium infantis, B. adolescentis, B. bifidum and Lactobacillus acidophilus to study its effect on microbial populations and medium pH. Finally, Escherichia coli, Salmonella, Staphylococcus aureus and Candida albicans were employed as pathogenic bacteria to explore the antimicrobial activity of EGCG and GTE. The results demonstrated that EGCG extractive could be beneficial for the proliferation of Bifidobacterium and L. acidophilus and also inhibit some pathogenic bacteria. In conclusion, both EGCG extractive and GTE had prebiotics activities and the effects of EGCG extractive were superior to those of GTE.

Green tea extract and its major component epigallocatechin gallate inhibits hepatitis B virus in vitro

2008 ◽  
Vol 78 (3) ◽  
pp. 242-249 ◽  
Author(s):  
Jun Xu ◽  
Jue Wang ◽  
Fei Deng ◽  
Zhihong Hu ◽  
Hualin Wang
Keyword(s):  
Hepatitis B Virus ◽  
Hepatitis B ◽  
Green Tea ◽  
Epigallocatechin Gallate ◽  
Green Tea Extract ◽  
B Virus ◽  
Tea Extract

Green tea and green tea extract in oncological treatment: A systematic review

2021 ◽  
pp. 1-13
Author(s):  
Fanny Wiese ◽  
Sabine Kutschan ◽  
Jennifer Doerfler ◽  
Viktoria Mathies ◽  
Jens Buentzel ◽  
...  
Keyword(s):  
Systematic Review ◽  
Green Tea ◽  
Methodological Quality ◽  
Meta Analysis ◽  
Specific Antigen ◽  
Intervention Group ◽  
Epigallocatechin Gallate ◽  
Oncological Treatment ◽  
Complementary Method ◽  
Tea Extract

Abstract. Purpose: Teas are an essential part of traditional phytotherapy. The aim of this systematic review is to assess the clinical evidence using green tea catechins in cancer care. Methods: A systematic search was conducted searching five electronic databases concerning the effectiveness and risks of epigallocatechin gallate (EGCG) on cancer patients. Results: Seven studies with 371 patients were included. Patients were mainly suffering from breast and prostate cancer. Dosing ranged from 28 mg to 1600 mg EGCG, intervention time from 7 days to 6 months with different applications (topical 2 studies; oral 5 studies). The studies showed heterogeneous methodological quality and results leading not to conduct a meta-analysis. There was a small decrease in prostate-specific-antigen levels in one study (N=60; T0:(mean±SD) 9.6±5.2 ng/ml, T1: 8.4±4.3 ng/ml vs. T0: 9.9±8.5 ng/ml, T1: 10.0±9.0 ng/ml; p=0.04), whereas in a second study only a trend was seen. Topical green tea was as effective as metronidazole powder in reducing the odor of fungating malignant wounds (1 study; N=30) with a consequent increase in quality of life (QoL) (p<0.001), improvement of appetite (p<0.001), malodorous control (p<0.001), social activities (p<0.001). Radiotherapy-induced diarrhea was lower in the green tea intervention group compared to placebo (1 study; N=42; week 4+5: without diarrhea p=0.002). Conclusions: The studies suggest that EGCG is as effective as a local antibiotic in malodorous control and improvement of QoL of fungating malignant wounds. Green tea could be a possible complementary method for treating acute radiation-induced diarrhea. Due to limitations, further studies with higher methodological quality and larger sample sizes are needed.

Potential role of green tea extract and epigallocatechin gallate in preventing bisphenol A-induced metabolic disorders in rats: Biochemical and molecular evidence

Phytomedicine ◽  
2021 ◽  
pp. 153754
Author(s):  
Mahdieh Sadat Mohsenzadeh ◽  
Bibi Marjan Razavi ◽  
Mohsen Imenshahidi ◽  
Seyed Abbas Tabatabaee Yazdi ◽  
Seyed Ahmad Mohajeri ◽  
...  
Keyword(s):  
Bisphenol A ◽  
Green Tea ◽  
Metabolic Disorders ◽  
Potential Role ◽  
Epigallocatechin Gallate ◽  
Green Tea Extract ◽  
Molecular Evidence ◽  
Tea Extract

scholarly journals Aldose Reductase Differential Inhibitors in Green Tea

Biomolecules ◽  
2020 ◽  
Vol 10 (7) ◽  
pp. 1003 ◽  
Author(s):  
Francesco Balestri ◽  
Giulio Poli ◽  
Carlotta Pineschi ◽  
Roberta Moschini ◽  
Mario Cappiello ◽  
...  
Keyword(s):  
Gallic Acid ◽  
Green Tea ◽  
Aldose Reductase ◽  
Active Site ◽  
Inhibitory Action ◽  
Computational Study ◽  
Epigallocatechin Gallate ◽  
Polyol Pathway ◽  
Differential Inhibition ◽  
Tea Extract

Aldose reductase (AKR1B1), the first enzyme in the polyol pathway, is likely involved in the onset of diabetic complications. Differential inhibition of AKR1B1 has been proposed to counteract the damaging effects linked to the activity of the enzyme while preserving its detoxifying ability. Here, we show that epigallocatechin gallate (EGCG), one of the most representative catechins present in green tea, acts as a differential inhibitor of human recombinant AKR1B1. A kinetic analysis of EGCG, and of its components, gallic acid (GA) and epigallocatechin (EGC) as inhibitors of the reduction of L-idose, 4-hydroxy2,3-nonenal (HNE), and 3-glutathionyl l-4-dihydroxynonanal (GSHNE) revealed for the compounds a different model of inhibition toward the different substrates. While EGCG preferentially inhibited L-idose and GSHNE reduction with respect to HNE, gallic acid, which was still active in inhibiting the reduction of the sugar, was less active in inhibiting HNE and GSHNE reduction. EGC was found to be less efficient as an inhibitor of AKR1B1 and devoid of any differential inhibitory action. A computational study defined different interactive modes for the three substrates on the AKR1B1 active site and suggested a rationale for the observed differential inhibition. A chromatographic fractionation of an alcoholic green tea extract revealed that, besides EGCG and GA, other components may exhibit the differential inhibition of AKR1B1.

Green tea extract and its major polyphenol (−)-epigallocatechin gallate improve muscle function in a mouse model for Duchenne muscular dystrophy

2006 ◽  
Vol 290 (2) ◽  
pp. C616-C625 ◽  
Author(s):  
Olivier M. Dorchies ◽  
Stéphanie Wagner ◽  
Ophélie Vuadens ◽  
Katri Waldhauser ◽  
Timo M. Buetler ◽  
...  
Keyword(s):  
Duchenne Muscular Dystrophy ◽  
Muscular Dystrophy ◽  
Mouse Model ◽  
Green Tea ◽  
Epigallocatechin Gallate ◽  
Green Tea Extract ◽  
Triceps Surae ◽  
Muscle Quality ◽  
Muscle Adaptation ◽  
Tea Extract

Duchenne muscular dystrophy is a frequent muscular disorder caused by mutations in the gene encoding dystrophin, a cytoskeletal protein that contributes to the stabilization of muscle fiber membrane during muscle activity. Affected individuals show progressive muscle wasting that generally causes death by age 30. In this study, the dystrophic mdx 5Cv mouse model was used to investigate the effects of green tea extract, its major component (−)-epigallocatechin gallate, and pentoxifylline on dystrophic muscle quality and function. Three-week-old mdx 5Cv mice were fed for either 1 or 5 wk a control chow or a chow containing the test substances. Histological examination showed a delay in necrosis of the extensor digitorum longus muscle in treated mice. Mechanical properties of triceps suræ muscles were recorded while the mice were under deep anesthesia. Phasic and tetanic tensions of treated mice were increased, reaching values close to those of normal mice. The phasic-to-tetanic tension ratio was corrected. Finally, muscles from treated mice exhibited 30–50% more residual force in a fatigue assay. These results demonstrate that diet supplementation of dystrophic mdx 5Cv mice with green tea extract or (−)-epigallocatechin gallate protected muscle against the first massive wave of necrosis and stimulated muscle adaptation toward a stronger and more resistant phenotype.

The MIRACLE trial: A randomized, controlled trial comparing green tea extract versus placebo for the prevention of metachronous colon adenomas in a screening population.

2015 ◽  
Vol 33 (3_suppl) ◽  
pp. TPS786-TPS786 ◽  
Author(s):  
Thomas Jens Ettrich ◽  
Julia Stingl ◽  
Rainer Muche ◽  
Katrin Claus ◽  
Baerbel Reiser ◽  
...  
Keyword(s):  
Green Tea ◽  
Controlled Trial ◽  
Epigallocatechin Gallate ◽  
Genetic Alterations ◽  
Colorectal Polyps ◽  
Green Tea Extract ◽  
Colorectal Adenomas ◽  
Tissue Samples ◽  
Increased Risk ◽  
Tea Extract

TPS786 Background: Prevention of colorectal cancer is a major health care issue. After polypectomy there is an increased risk of polyp recurrence and various means of chemoprevention have been tried to prevent this. NSAIDs have been shown to be effective but confer side effects such as gastrointestinal bleeding. Nutraceuticals such as polyphenols from tea plants have demonstrated remarkable therapeutic and preventive effects in molecular, epidemiological and some clinical trials. However, their value in preventing colorectal polyps has not been demonstrated in a large, randomized trial. The beneficial safety profile of decaffeinated green tea extract and accumulating evidence of its cancer preventive potential justify and require, in our view, a validation of this compound for the nutriprevention of colorectal adenoma. Good accessibility and low costs might render this neutraceutical a top candidate for wider use as nutritional supplement in colon cancer prevention. Methods: Randomized, double blinded, placebo-controlled, multicenter trial. After a one month run-in period with verum, 918 patients (age: 50-80 years) who have undergone polypectomy within the last 6 months will be randomized to receive either decaffeinated green tea extract (containing 150 mg epigallocatechin gallate (EGCG) two times daily) or placebo over a period of three years. Primary outcome: Incidence of metachronous colorectal adenomas (tubulovillous, tubular, villous, serrated lesions) at the 3 year follow-up colonoscopy. Secondary outcomes: Occurrences, number, localization, size and histological subtypes of adenomas, frequency of colorectal carcinoma. In addition, genetic and biochemical biomarkers in blood samples and genetic alterations (Ras, B-raf, microRNAs) in tissue samples of adenomas will be analyzed (biobanking subprojects). Additionally, nutrikinetics and nutrigenetics of EGCG and other catechins will be assessed in healthy volunteers. Patient recruitment has started in November 2011. At September 2014, 785 patients were recruited and 651 patients were randomized. We expect the last patient out in Spring 2018. (Trial identifier NCT01360320) Clinical trial information: NCT01360320.

Sign in / Sign up

Export Citation Format

Share Document